Table 1 Treatment characteristics
From: Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
Sunitinib treatment | Total n = 99 |
|---|---|
Sunitinib first line, n (%) | 70 (71) |
Sunitinib second line, n (%) | 29 (29) |
Side effects leading to discontinuation of treatment, n (%) | 22 (22) |
 First line | 16 |
 Second line | 6 |
Treated until progression/end of follow-up, n (%) | 77 (78) |
 First line | 54 |
 Second line | 23 |
Median PFS, months (range) | 7 (0,5–34) |
 First line | 7,8 (0,5–34) |
 Second line | 6 (1–24) |
Still under treatment, n (%) | 11 (14) |